Cure My Disease

Don't miss your cure!

 Log in / Sign up

Stick-On ultrasound patch could spot liver damage without a specialist

NCT ID NCT07716384

Diagnosis Sponsor: Second Affiliated Hospital of Xi'an Jiaotong University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This study tests a new wearable patch-type ultrasound probe that sticks to the skin over the liver to measure stiffness, which can indicate scarring (fibrosis) or cirrhosis. Researchers will compare its accuracy to the standard FibroScan device in 150 adults with chronic liver disease. If the patch works well, it could offer a simpler, more portable way to screen for liver damage.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a wearable patch-type ultrasound probe
What this could lead to
If accurate, this patch could make liver fibrosis screening more accessible and convenient, reducing the need for specialized equipment and trained operators.
What could go wrong
This is a small, early-stage study comparing the patch to an existing device, not a definitive test. The patch may not be as accurate as standard methods, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Oct 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with confirmed or suspected chronic liver disease (including chronic viral hepatitis, non-alcoholic fatty liver disease, and alcohol-related liver disease) presenting for routine clinical evaluation, consecutively enrolled to capture a continuous spectrum of liver fibrosis severity ranging from no/mild fibrosis to cirrhosis. All eligible patients will undergo liver stiffness measurement using both the investigational wearable patch-type ultrasound probe and transient elastography (FibroScan) as the reference standard.

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Confirmed or suspected chronic liver disease (including but not limited to chronic viral hepatitis, non-alcoholic fatty liver disease, and alcohol-related liver disease) * Scheduled to undergo, or have recently undergone, transient elastography (FibroScan) as part of routine clinical care * Age ≥ 18 years * Willing and able to provide signed informed consent Exclusion Criteria: * Ascites (may interfere with liver stiffness measurement by either device) Body mass index (BMI) ≥ 35 kg/m² (may reduce measurement reliability of transient elastography) * Acute hepatitis or acute-on-chronic liver failure at the time of enrollment * History of liver transplantation * Hepatocellular carcinoma or other space-occupying liver lesions * Pregnant women * Skin lesions, infection, or scarring at the intended probe application site (right lobe of the liver, intercostal space) * Unable to cooperate with the measurement procedure (e.g., severe cognitive impairment)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic hepatitis B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection cirrhosis of liver fibrotic liver disease hepatitis B virus infection liver disorder metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatitis B, chronic Liver cirrhosis Liver fibrosis NAFLD - nonalcoholic fatty liver disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.